Ara 290 vs NAD+
Extensively Studied vs Extensively Studied
monitor Researched · 90% Both affect cellular metabolism; monitor for additive effects.
Molecular Data
Ara 290 NAD+
Weight 1,257 Da 663.43 Da
Half-life ~20 minutes (SubQ), ~2 minutes (IV) 1-4 hours (intracellular)
Chain 11 amino acids —
Type Engineered peptide Coenzyme
Key Benefits
Ara 290
01 Proven tissue protection
02 Nerve regeneration
03 Anti-inflammatory effects
04 Excellent safety profile in clinical trials
NAD+
01 Restores mitochondrial function and ATP synthesis
02 Enhances glucose and fat metabolism
03 Improves oxygen utilization and endurance
04 Activates DNA repair mechanisms
05 Supports longevity pathways via sirtuins
06 Improves mental clarity and focus
Dosing Protocols
Ara 290
4 mg daily / Once daily
Neuropathy Treatment 4 mg daily Once daily
Tissue Protection 1-8 mg daily Once daily
Acute Intervention 2 mg 3x weekly
NAD+
IV: 250-1000mg; IM/SubQ: 100-500mg; Intranasal: 25-50mg; Oral precursors: 100-500mg NMN/NR / IV: 1-2x weekly; IM/SubQ: 2-3x weekly; Intranasal: 1-2x daily; Oral: daily
IV Infusion 250-1000mg 1-2x weekly
IM/SubQ 100-500mg 2-3x weekly
Side Effects
Ara 290
Excellent safety profile in clinical trials with no serious drug-related adverse events
NAD+
Mild flushing during IV infusion
Temporary nausea
Contraindications
Recent anti-TNF therapy (within 6 months)
EPO use (within 2 months)
Pregnancy
BMI > 34 kg/m²
IV administration requires medical supervision
Avoid alcohol during treatment
Maintain consistent dosing schedule
Research Evidence
Ara 290 NAD+
Status Extensively Studied Extensively Studied
References 5 studies 6 studies
Latest 2024 November 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.